High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer

Table 1 Clinicaopathological variables and the expression of PFKFB4

Variable	Number of patients	PFKFB4 expression		p-value^a
Variable	Number of patients	Negative number (%)	Positive number (%)	p-value^a
Total	200	102 (51.0)	98 (49.0)
Age (years)				0.453
≤ 50	113	55 (48.7)	58 (51.3)
> 50	87	47 (54.0)	40 (46.0)
Menopausal status				0.837
Premenopausal	121	61 (50.4)	60 (49.6)
Postmenopausal	79	41 (51.9)	38 (48.1)
Tumor size (cm)				0.168
≤ 2	95	50 (52.6)	45 (47.4)
> 2, ≤ 5	91	48 (52.7)	43 (47.3)
> 5	8	1 (12.5)	7 (87.5)
Cannot be measured	6	3 (50.0)	3 (50.0)
Lymph node status				0.890
Negative	99	50 (50.5)	49 (49.5)
Positive	101	52 (51.5)	49 (48.5)
Grade				0.716
Grade 1	2	1 (50.0)	1 (50.0)
Grade 2	94	52 (55.3)	42 (44.7)
Grade 3	56	26 (46.4)	30 (53.6)
Unknown	48	23 (47.9)	25 (52.1)
ER status				0.021
Negative	112	49 (43.8)	63 (56.3)
Positive	88	53 (60.2)	35 (39.8)
PR status				0.059
Negative	113	51 (45.1)	62 (54.9)
Positive	87	51 (58.6)	36 (41.4)
HER2 status				0.120
Negative	99	45 (45.5)	54 (54.5)
Positive	101	57 (56.4)	44 (43.6)
Subtype^b				0.068
Luminal	100	58 (58.0)	42 (42.0)
HER2-enriched	50	25 (50.0)	25 (50.0)
Triple-negative	50	19 (38.0)	31 (62.0)

ER estrogen receptor, HER-2 human epidermal growth factor receptor 2, PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4, PR progesterone receptor
^aBased on the Pearson χ² test (Fisher’s exact test was used when needed)
^bDefinitions of subtypes: luminal (ER- and/or PR-positive), HER-2-enriched (ER- and PR-negative, HER-2-positive), and triple-negative (ER-negative, PR-negative, and HER-2-negative)

ISSN: 1475-2867